Tailin mRNA Drug Manufacturing Equipment & Solutions: From Laboratory to Commercialization

Learn how advanced technologies, including closed cell & gene therapy isolator systems, aseptic filling isolator, and the AST series rapid sterility testing systems, help pharmaceutical manufacturers ensure GMP compliance.

1. Introduction: Why Advanced mRNA Drug Manufacturing Equipment is Crucial for Commercialization

Since 2020, mRNA vaccines have rapidly demonstrated the commercial potential of nucleic acid therapeutics. As mRNA technology continues to expand into areas such as cancer immunotherapy, protein replacement therapy, and gene-editing-assisted therapies, innovative pharmaceutical companies worldwide are accelerating the transition of mRNA drugs from laboratory research to clinical development and commercial manufacturing.

However, compared with conventional small-molecule drugs, mRNA drugs present unique manufacturing challenges:

Poor Molecular Stability
Sensitive to the Production Environment
High Sterility Assurance Requirements
Complex Manufacturing Process
Challenging Batch-to-Batch Consistency Control
As a result, establishing a GMP-compliant manufacturing system is a critical factor in determining whether mRNA drugs can move successfully into scalable commercial production.

From FDA requirements for sterile drug manufacturing to EU GMP Annex 1 -Manufacture of Sterile Medicinal Products, global regulatory frameworks continue to place greater emphasis on Contamination Control Strategy (CCS), aseptic process design, isolation technologies, and end-to-end risk management. FDA requirements for sterile drug manufacturing call for appropriate CGMP controls to minimize the risk of microbial contamination, while the 2022 revision of EU GMP Annex 1 emphasizes a comprehensive CCS covering facilities, equipment, personnel, processes, and monitoring systems, with engineering controls used to reduce contamination risks associated with human intervention.

Against this backdrop, advanced manufacturing equipment has become a critical part of the infrastructure required for mRNA commercialization.

2. Tailin Isolator Systems: Closed GMP-Compliant Manufacturing for Advanced Biopharmaceuticals
2.1 Regulatory Trend: Isolation Technologies Are Becoming a Key Direction in Advanced Biopharmaceutical Manufacturing
Traditional cleanrooms rely heavily on environmental control to maintain sterile conditions. However, as advanced biopharmaceutical products become increasingly complex, environmental control alone may not be sufficient to meet the requirements of future commercial manufacturing.

EU GMP Annex 1 emphasizes:

Minimizing human intervention;
Prioritizing automation and closed systems;
Using engineering controls to reduce contamination risks.
FDA also recognizes the value of closed systems and advanced technologies such as isolators in reducing the potential for contamination from personnel and the surrounding environment during sterile processing.

For mRNA drugs, a reliable contamination control system is required throughout the entire manufacturing process—from plasmid template preparation, in vitro transcription, and purification to lipid nanoparticle (LNP) encapsulation and aseptic filling.

2.2 Tailin Cell & Gene Therapy Isolator Solution
To support the commercialization of Advanced Therapy Medicinal Products (ATMPs), Tailin has developed Cell and Gene Therapy Isolator designed to meet GMP manufacturing requirements.

The system uses customized closed isolator technology to replace conventional open operations, providing a controlled and enclosed operating environment for cell processing, cell and plasmid handling, viral vector filling and dispensing, and quality control.

Key benefits include:

(1) Reducing Contamination Risks Associated with Open Operations
The isolator creates an independent Grade A operating environment that physically separates Personnel, Products and the Surrounding Environment.

This helps minimize the risk of microbial contamination associated with human intervention.

Tailin closed isolator system for cell and gene therapy and mRNA manufacturing

(2) Supporting Flexible Multi-Product and Multi-Batch Manufacturing
The future commercial manufacturing model for mRNA drugs is expected to feature:

Small batches, multiple products, and rapid changeovers.

Tailin’s modular isolation technology helps improve manufacturing flexibility and supports the rapid iteration and development of innovative pharmaceutical products.

2.3 Aseptic Filling Workstation: The Final Barrier for Commercial mRNA Drug Manufacturing
mRNA drug formulations typically feature:

High sensitivity to temperature;
Susceptibility to degradation;
Stringent sterility requirements.
Therefore, aseptic filling is not only critical to product quality but also directly affects the scalability of commercial manufacturing.

Under FDA sterile manufacturing requirements, sterile drug products must be manufactured using validated aseptic processes, with product safety ensured through appropriate equipment design, process controls, and validation strategies.

Tailin’s aseptic filling workstation integrates:

A closed operating environment;
Highly clean air protection;
Automated control;
Reduced manual intervention;
to help pharmaceutical manufacturers establish aseptic filling solutions suited to the future production requirements of mRNA drugs.

Tailin closed automatic aseptic filling isolator system

3. Tailin Rapid Sterility Testing Systems: Accelerating mRNA Drug Quality Release
3.1 Limitations of Traditional 14-Day Sterility Testing
The conventional growth-based sterility test described in USP <71> Sterility Tests requires an incubation period of at least 14 days. While this method remains an important compendial sterility test, its long turnaround time can present challenges for short-life products and products requiring rapid release.

This limitation has been recognized internationally.

USP <1071>, Rapid Microbial Tests for Release of Sterile Short-Life Products: A Risk-Based Approach, specifically notes that conventional growth-based sterility testing with an incubation period of at least 14 days is not suitable for certain short-life products or products intended for immediate use. The chapter supports the use of risk-based rapid microbiological approaches where appropriate.
EU GMP Annex 1 states that appropriate technologies, including rapid/alternative microbiological methods and continuous monitoring systems, should be considered to support rapid detection of potential microbial contamination in the environment and products.
FDA guidance on laboratory controls recognizes the potential of alternative microbiological methods to shorten testing time, provided that the alternative method demonstrates performance equivalent to or better than the compendial method. FDA has also noted that innovations such as rapid microbiological methods can improve operational feedback and batch release efficiency when they provide equivalent or better detection capability.
The Microbial Respiration Signal Method has emerged as one of the recommended technical approaches.

Microbial Respiration Signal Method

3.2 Tailin AST Series Rapid Sterility Test System
The Tailin AST-300 Rapid Sterility Test System uses microbial respiration and metabolic signal detection technology. Through automated incubation and intelligent result interpretation, the system enables rapid sterility testing.

Supports rapid microbiological testing;
Enables automated incubation;
Reduces errors associated with manual observation;
Improves quality control efficiency.
For short-life products and advanced therapies, sterility testing is closely associated with product quality, clinical-use windows, and patient safety.

Respiration-based microbiological methods continuously monitor CO₂ signals generated by microbial metabolism, transforming the conventional incubation process from a manually observed endpoint test into a dynamic process that can be recorded, analyzed, and traced.

Tailin AST series rapid sterility test system

For future mRNA drug manufacturing, rapid microbiological testing can become an important link between manufacturing efficiency, quality assurance, and patient safety.

4. From Technology Provider to Industry Enabler: Tailin’s Next-Generation Life Science Equipment Ecosystem
Tailin’s Technology portfolio: Your Trusted Partner in Life Science

Founded in 2002, Tailin is a life science systems solution provider.

Tailin continues to innovate across biotechnology, precision medicine, and pharmaceutical engineering, providing integrated equipment, precision instruments, and supporting consumables for life science research and industrial applications.

Today, Tailin has accumulated:

More than 30 pieces of equipment representing domestic firsts or filling industry gaps;
Participation in the development of more than 30 standards;
More than 300 proprietary intellectual property rights;
More than 20 scientific research projects.
From cell therapy to gene therapy and mRNA-based nucleic acid therapeutics, the life science industry is entering a new era of equipment-driven innovation.

Tailin — Empowering Innovative Medicines from the Laboratory to the Future.